Issue 24 | 2016
Get instant access to latest e-book

latest news


Aug 2016

Aurobindo, Intas in race for $1 billion buyout of Teva UK, submit binding offers

Home grown drug makers AurobindoBSE and Intas are among the final contenders for the UK and Irish portfolio of Israeli generics behemoth Teva put up for sale to comply with European antitrust regulations Both players have submitted binding offers of around billion on Friday along with ..


Aug 2016

Biotie Therapies: BTT1023 receives Orphan Drug Designation in US

FDA has granted Orphan Drug Designation for Bioties BTT drug candidate for treatment of primary sclerosing cholangitis PSC BTT is currently being studied for PSC in Phase a study BUTEO study Says twostage study design for BUTEO includes a preplanned interim analysis expected in first half of Source reuterscom ..


Aug 2016

FDA warns former Sun Pharma U.S. drug factory over quality concerns

The US Food and Drug Administration has pulled up a former Sun Pharmaceutical drug factory for knowingly releasing lots of the hypertension drug clonidine last year despite proof that the raw materials used may have been contaminated This is one of a series of quality concerns tied to the Philadelphia Pennsylvania fa..


Aug 2016

Britain's FTSE edges lower as pharmaceuticals weigh again

Britains top share index edged lower on Friday set to finish the week with falls as recent weakness in the pharmaceuticals continued with investors wary over political risk in the sector By GMT the FTSE was down points or percent at down percent for the week and set for a second straight weekly fall Investors w..

events

28 - 01

Aug 2016

FIP World Congress of Pharmacy and Pharmaceutical Sciences 2016

FIP Congresses and Conferences
Hilton Buenos Aires

29 - 30

Aug 2016


knowledge bank

  • interviews

    Datwyler Pharma Packaging

    Senior Manager Global Scientific Affairs
    Renaud Janssen, Ph.D. is the Senior Manager of Global Scientific Affairs at Datwyler Pharma Packaging. He frequently presents on international conferences on subjects related to elastomeric and aluminium/plastic closures for pharm..

  • Articles

    When Orphan Drugs Make All the Difference

    Orphan drugs those medications that are typically produced in small quantities for limited patient populations are growing in importance worldwide Once largely considered too costly to produce given the limited number of patients affected by a particular disease new technology and new breakthroughs in biopharma have changed the landscape allowing more orphan drugs to be produced than ever before t..

  • Research Insights

    Targeting Blood-brain-barrier Transcytosis – Perspectives For Drug Delivery

    Abstract Efficient transcytosis across the bloodbrainbarrier BBB is an important strategy for accessing drug targets within the central nervous system CNS Despite extensive research the number of studies reporting successful delivery of macromolecules or macromolecular complexes to the CNS has remained very low In order to expand current research it is important to know which receptors are selective and abundant on the BBB so that novel CNStarge..

editorial Section

  • Competing on Alignment

    SWOT is both the most powerful and least understood strategic management tool Used correctly it translates the outputs of many other market analyses into a small number of key issues..

  • Future Trends in Ion Channel and Solute Transporter Drug Discovery

    Gene family members of the ion channel and solute transporter SLC families represent both historical targets of pharmaceutical significance and serve as exciting opportunities for current and future therapeutic development The common property of ion movement for many of the SLCs lends itself to considering platforms used in ion channel research to enable early drug discovery In addition the convergence of advances in both genetic analysis and assay technology bodes well for the identification of the next generation of ion channel and transporterbased drugs in the near future..

  • Issues & Concerns in Conducting Clinical Trials in India

    Issues like approval delays deficiencies of functioning of CROs and other stake holders liabilities and compensation to injured subjects insurance issues etc still remain in India which has made multinational companies to rethink on opting for India to conduct clinical trials in India recently There is a need for a law to ensure that the people who undergo clinical trials are not exploited and should be well informed about risk as well to provide..

  • Innovation Challenges in Manufacturing

    Most firms in the pharmaceutical industry think globally to expand demand for their products There are amenities from which firms leverage to launch a strategy to gain global market share These amenities include the regulatory dimension which helps reassign resources within and outside the firm..

  • Quality by Design

    The article presents a novel approach to applying Quality by Design QbD principles to the development of analytical methods Common critical parameters in HPLC gradient time temperature pH of the aqueous eluent and stationary phase are evaluated within the Quality by Design framework It is useful for the robust analytical method development and Design Space optimisation..

  • Peptides Remain a Growth Story

    Cloud solutions offer immediate returns in improving operational performance and reducing costs Multiple approaches to cloud solutions will be needed to satisfy life science industry needs complicating the development of a coherent cloud strategy..